Skip to content
Main content
Axent Biosciences Inc. is a new biotech venture spun out of UC Berkeley. Building on 20+ years of stem cell expertise and leveraging 10+ years of biomaterials technology development in the Schaffer Lab, we will address unmet medical needs for human diseases and disorders using next generation cell therapies. Specifically, we engineer biomaterial technology for two main bottlenecks in the development pipeline for stem cell therapy: manufacturing and implantation. Our team has strong start-up, scientific, and operations experience ideally suited to develop novel stem cell products, and we aim to progress to pre-clinical studies on lead candidates in the second half of 2020, with a focus on therapies for degenerative disorders of the Central Nervous System (CNS).
Nov 16, 2022

CEO Greg Went appreciates that our time on Earth is short. What he cares about is helping patients with medicines that work. He doesn’t have time for the ego that some scientists have tied up in the technologies they’re developing. He admits that, early on, even his company was too into itself. “What Reflexion lacked early on was the mentality of ‘why develop this technology if it’s not better than monoclonal antibodies.’ ‘Same as’: we don’t need that. We need products that are a factor of two to ten times better than the standard of care.”

Nov 04, 2022

Every aspect of our building is innovative! “What we ended up with was this really cool system of ‘stealth’ looking concrete walls,” Price explains. “They had extreme angles – from 45 degrees to 60 degrees, that were top-cast finished with an EcoSand final finish.” Being large stretches of concrete, there was also concern about skateboarders, so a custom stainless-steel system of skateboard deterrence was designed to replicate the human genome and installed on the face of the battered walls.

Nov 01, 2022

But while continuing to work in Africa with the Clinton Health Access Initiative, she learned she couldn't get far enough away. People were surprised when they learned that the nearly 6-foot-tall, athletic-looking Digovich — a former basketball player in college — was living with Type 1 diabetes, a diagnosis in Africa that often translates into stunted growth, amputation and high mortality. "Ultimately, I got really angry and the switch flipped. If I was born there, I would be dead. That really hit close to home," she said. "I took stock of my career and threw myself into the diabetes space."